samedan logo
 
 
spacer
home > pmps > winter 2021 > a dose of industrial edge for pharmaceutical manufacturing
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

A Dose of Industrial Edge for Pharmaceutical Manufacturing

The pharmaceutical and life science sector has not escaped the effects of the pandemic, with employees working from home and only critical staff and visitors allowed to visit production sites. We’ve been reminded how fragile the world is, and how something we can’t see can wreak havoc on a global scale. The word ‘biologics’ is now commonplace on the world stage, and biologic manufacturers continue to search for a ‘100% vaccine’, which is an illustration of how the community is coming together to accelerate the response. Governed by strict regulations, few other industry sectors can claim they are regulated as stringently. With a vaccine set to be produced on a global scale, by multiple manufacturers who are under enormous pressure to deliver ‘the antidote’, how can they adhere to FDA regulations and comply with GMP in a fast-moving operation? How can their technical partner help them maximise their value chain?

The key drivers within this sector are well affirmed as: time-to-market, quality/regulations, flexibility, and efficiency. The ability to up-scale from clinical trials of small batches to full production, while maintaining quality, is paramount.

Before the COVID-19 pandemic, the Industry 4.0 evolution had already impacted the way pharma adopts new technologies and digitalises its manufacturing plants. The goal was to remain on top of the game by addressing the well-versed industry drivers. These factors have emanated from market forces, such as our demand for new medicines, new entrants into the market, uncertainty, complexity, and cost.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Andrew Matthews, Vertical Account Manager, Pharmaceutical and Life Science, at Siemens Digital Industries is helping pharmaceutical and life science organisations embrace digitalisation. Andrew supports the automation of their value chain to get the products from the lab to the patient more swiftly. He currently supports the Institute of Sales Management (ISM) as a mentor and is part of their advisory committee reviewing new members and helping the next generation of sales professionals. He is a keen cyclist and skier.
spacer
Andrew Matthews
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera to build state-of-the-art manufacturing facility in Poland to serve more customers and patients

Based in Szczecin, this facility extends Nemera’s manufacturing capabilities and will bring more drug delivery device solutions to patients. Following the dynamic growth of the drug delivery devices market, as a world leader, Nemera is thrilled to extend its manufacturing capabilities in Poland.
More info >>

White Papers

eSource: Reducing Site Workload for Better, Faster, Safer Clinical Trials

Clinical Ink

Unlike traditional electronic data capture (EDC), SureSource, Clinical Ink’s eSource platform, was designed from the beginning to minimize clinical trial complexity for site users. A Site Impact Survey provides scientific evidence regarding the impact of SureSource from 517 site users. Results confirm it significantly reduces workload, lessens queries, and improves data quality compared to paper and EDC. In this white paper, we quantitatively evaluate survey outcomes, provide qualitative feedback from survey respondents, and highlight the observed benefits of SureSource for transforming clinical research.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement